在炎症性肠道疾病和刺激性肠道综合征中的内类系统调节:系统审查和元分析的方案
在PubMed上查看摘要
概括
此摘要是机器生成的。这份系统性综述考察了大麻,大麻素和其他内分泌系统 (ECS) 调节剂在炎症性肠道疾病 (IBD) 和刺激性肠道综合征 (IBS) 中的内脏疼痛. 综合了有关益处和危害的证据,以指导治疗这些常见的胃肠疾病.
科学领域
- 胃肠病学和疼痛治疗
- 药理学和治疗学
- 系统审查和元分析
背景情况
- 内脏疼痛对炎症性肠病 (IBD) 和刺激性肠综合征 (IBS) 的患者有显著影响.
- 内分泌系统 (ECS) 在胃肠功能和疼痛调节中起着至关重要的作用,使其成为治疗点.
- 目前用于IBD和IBS内脏疼痛的治疗方法往往存在局限性,因此需要探索新的方法.
研究的目的
- 系统地审查评估大麻,大麻类药物,大麻制药 (CBM) 和其他ECS调节器在IBD和IBS患者的随机对照试验 (RCT).
- 与安慰剂或其他干预措施相比,评估药物学ECS调节的益处和危害.
- 综合目前关于ECS调节剂治疗内脏腹痛和IBD和IBS相关并发症的有效性和安全性的证据.
主要方法
- 在多个数据库 (CENTRAL,MEDLINE,PubMed,EMBASE,Web of Science) 和临床试验注册表中进行系统的文献搜索.
- 包括对任何对照组评估任何大麻,大麻素,CBM或ECS调节剂的RCT.
- 根据PRISMA指南进行数据提取和综合,包括偏差风险评估 (Cochrane风险偏差2) 和必要时的元分析,使用GRADEpro GDT评估证据的确定性.
主要成果
- 该审查综合了ECS调节器在减少内脏疼痛至少30%和50%的有效性.
- 评估的次要结果包括疼痛强度的变化,功能状态 (身体和情绪),疲劳,睡眠,生活质量和胃肠道症状的严重程度.
- 在IBD和IBS群体中,与ECS调节相关的不良反应被系统地记录下来.
结论
- 本系统性审查提供了关于使用内分泌系统调节剂治疗IBD和IBS内脏疼痛的证据的全面概述.
- 通过突出这些干预措施的好处和危害,这些发现将为临床实践提供信息,并指导未来的研究方向.
- 这项研究旨在澄清ECS调节在消化道疾病中治疗虚弱的内脏疼痛和相关症状的作用.
相关概念视频
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...

